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Cell�lar dr�g resistance�� either acq�ired or intrin­
sic�� remains a major ca�se of fail�re in chemotherapy 
of hematological malignancies and solid t�mors. Cells 
exposed to toxic compo�nds can develop resistance 
by a n�mber of mechanisms incl�ding increased excre­
tion�� decreased �ptake�� increased detoxification or 
alteration of target proteins [�]. Several of these path­
ways can lead to m�ltidr�g resistance �MDR��. In this 
case�� cells are resistant to several commonly �sed 
dr�gs in addition to initially applied compo�nd [�]. The 
ATP­binding cassette �ABC�� genes play the leading 
role in the development of MDR. These genes repre­
sent the largest family of transmembrane proteins that 
bind ATP and �se the energy to drive the transport of 
vario�s molec�les across cell membrane [��4].
One known mechanism�� contrib�ted to this phenome­
non�� involves expression of P­glycoprotein �P­gp��. P­gp 
is incl�ded in large s�per family of transport proteins�� 
termed ATP Binding Cassette �ABC�� [�]. MDR1 gene�� 
located on chromosome 7�� encodes a �7� kDa glycopro­
tein. P­gp possesses wide s�bstrate specificity for str�c­
t�rally different dr�gs and�� conseq�ently�� mediates dr�g 
resistance to variety of dr�gs�� incl�ding vinca alkaloids�� 
anthracyclines�� epipodophyllotoxins�� taxols�� actinomycin 
D�� cardiac glycosides�� imm�nos�ppressive agents�� gl�­
cocorticoids�� anti­HIV protease inhibitors [�].
All the s�bstrates of P­gp are large hydrophobic and 
amphipathic molec�les�� altho�gh they have no str�c­
t�ral similarity. These molec�les are able to intercalate 
into the membrane and enter the cytosol by passive 
diff�sion. It is no longer believed that P­gp is a classi­
cal p�mp�� which binds s�bstrates from the extracell�lar 
fl�id and then transports these over the membrane. 
Hydrophobic compo�nds that are s�bstrates for P­gp 
do not f�lly penetrate into the cytoplasm of cells that 
express P­gp. Interaction of s�bstrate with P­gp has 
been shown to take place within the membrane.
Since a wide spectr�m of dr�gs is affected by MDR1 
gene�� it is an attractive candidate to st�dy the phenome­
non of dr�g resistance [4]. MDR1 gene overexpression 
in hematological malignancies �ac�te myelogeno�s 
le�kemia�� m�ltiple myeloma�� malignant lymphomas�� at 
the time of diagnosis points on its clinical importance as 
prognostic factor [��� 7]. In vitro research provides signifi­
cant opport�nities to st�dy the mechanisms of m�ltidr�g 
resistance. Resistant cell lines co�ld be established by 
grad�al increase of concentration of cytotoxic agent [�].
In present st�dy h�man ac�te myeloid le�kemia 
cell line resistant to vincristine �HL��/VCR�� was estab­
lished by grad�al �from passage to passage�� increase 
of VCR concentration�� and then cross­resistance to 
Ara­C in established resistant line was detected.
Chemicals. RPMI ��4��� fetal calf ser�m�� penicil­
lin�� streptomycin ��� mg/ml���� L­gl�tamine and trypan 
bl�e sol�tions were obtained from Biological Ind�stries 
�Israel��. Trizol reagent was obtained from Life Technolo­
gies �Israel��. Moloney M�rine Le�kemia Reverse­Trans­
criptase�� Taq DNA polymerase�� RNAse inhibitor�� and 
DNA size marker ��������� bp�� were obtained from 
Fermentas �USA��. The set of deoxyn�cleotide �dNTP���� 
isopropanol�� agarose and MTT were from Sigma �USA��. 
PBS was obtained from Oxoid �England��. Diethylepyro­
carbonate �DEP­C�� was obtained from Applichem �Ger­
many��. Formaldehyde ��7%�� was obtained from Merck 
�Germany��. PCR primers and Oligo­dT were obtained 
from Integrated DNA Technologies �USA��. Chloroform 
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was obtained from Lab Scan Analytical Sciences �Ire­
land��. VCR and Ara­C were kindly provided by G�lhane 
Military Medical School �Ankara�� T�rkey��.
Cell culture. H�man ac�te myeloid le�kemia HL�� 
cells were kindly provided by G�lhane Military Medical 
School �T�rkey��. HL�� cells were maintained in RPMI ��4� 
growth medi�m�� containing ��% fetal calf ser�m �FCS�� and 
�% penicillin­streptomycin sol�tion�� at �7 oC in �% CO�.
Generation of resistant sublines. HL�� cells 
were exposed to grad�ally increasing concentration of 
VCR�� starting from � nM and �p to �� nM�� and resistant 
cells were selected�� passaged and exposed to higher 
concentration of VCR. In this way�� s�bpop�lations of 
cells with different degree of VCR resistance were 
generated. The level of resistance was defined by the 
VCR concentration at which the growth rate of cells 
was comparable to �ntreated parental cells.
Measurement of cell growth by 3-(4, 5-Dimethyl-
thiazol-2-yl)-2-5 diphenyltetrazolium-bromide (MTT) 
assay. The concentrations of VCR and Ara­C�� which in­
hibited cell growth by ��% �IC���� were eval�ated �sing 
MTT­assay [9]. HL�� cells �� × ��4 cells/well�� were plated 
into 9�­well plates�� containing ��� µl of c�lt�re medi�m 
in the absence or presence of different concentrations of 
VCR and Ara­C at �7 oC in �% CO� for 4� h. Then they were 
treated with � µl of MTT �� mg/ml�� for 4 h. The s�perna­
tants in the wells were discarded and dark bl�e crystals 
were dissolved with the addition of acidified isopropanol 
��.�4 N HCl in isopropanol��. Plates were examined with 
microplate reader at �7� nm�� and IC�� concentrations of 
compo�nd were determined from cell s�rvival plots [9]. For 
each concentration of dr�g�� � wells were co�nted.
RNA isolation. Total RNA was isolated from � x ��� HL�� 
and HL��/VCR cells�� �sing Trizol reagent �with g�anidi�m 
thiocyanate�� phenol and sodi�m citrate�� �Life Technolo­
gies�� Israel��. Q�antification of RNA was performed�� �sing 
UV spectrophotometer the wave length of ��� nm.
Reverse transcription-polymerase chain reac-  
tion (RT-PCR). RT­PCR was carried o�t for �� min at 
4� °C in a total vol�me of �� µl�� containing �� �nits of 
ribon�clease inhibitor�� �.� µg oligo­dT�� �.� mM of each 
dNTP�� ��� �nits of reverse transcriptase�� and � µg of 
total cell�lar RNA. When mRNA template was created�� 
PCR analysis was performed.
For eval�ation of MDR1 gene expression�� forward 
primer ��´TACAGTGGAATTGGTGCTGGG�´�� and re­
verse primer ��´TACAGTGGAATTGGTGCTGGG�´�� were 
�sed. The reaction mix with two primers was amplified 
d�ring �� cycles �94 °C�� �� s; �� °C�� 4� s; 7� °C�� � min���� 
�sing Taq DNA polymerase.
The mRNA of β�­microglob�lin was �sed as internal 
positive control. For eval�ation of β�­microglob�lin gene 
expression�� forward primer ��´CTTACTGAAGAATG­
GAGAGAGA�´�� and reverse primer ��´CTTACATGTCTC­
TATCCCACTT�´�� were �sed [��]. The reaction mix was am­
plified d�ring �� cycles �94 °C�� �� s; �� °C�� 4� s; 7� °C�� � min���� 
�sing Taq DNA polymerase. MDR� and β�­microglob�lin 
band intensities were meas�red densitometrically.
Expression of MDR1. The intactness of total RNA 
was confirmed by two sharp bands of ��S rRNA and ��S 
rRNA�� separated in denat�ring agarose gels and vis�alized 
by ethidi�m bromide �EtBr�� staining �nder UV light. The 
target MDR1 gene and the reference β�­microglob�lin 
gene were amplified by PCR. PCR prod�ct of MDR1 
gene responds to ��� bp fragment�� while the prod�cts of 
β�­microglob�lin gene to ��� bp fragment. The level of 
target gene expression is reflected in the ratio between 
intensities of two res�lting PCR prod�ct bands on gel.
In this st�dy�� we tried to determine the differences in ex­
pression levels of MDR1 gene in HL�� and HL��/VCR cells. 
β�­microglob�lin was �sed as an internal control since its 
expression does not change �pon expos�re to VCR [��]. 
Increase of VCR concentrations res�lted in increased 
expression of MDR1 gene �Fig. ���. Fig. � shows that there 
was no expression of MDR1 gene in control cells and 
HL�� cells�� treated with � nM of VCR. However�� HL�� cells 
expressed MDR1 gene at the doses of VCR > � nM �see 
Fig. ���. The res�lts strongly s�ggest that HL�� cells can 
s�rvive at higher concentrations of VCR and this resistance 
can be explained by overexpression of MDR1 gene.
Fig. 1. RT­PCR analysis of expression of MDR1 gene in parental 
�Lane ��� and VCR­resistant HL�� cells �lanes ��� 4 — � nM and 
�� nM VCR�� respectively��. Lane � — DNA ladder; lanes ��7 — 
beta microglob�lin levels were �sed as internal positive control 
Several dr�g resistance mechanisms�� in partic�lar with 
the involvement of P­gp�� were identified [��� ���� ��].
Cell cytotoxicity assay. For each dr�g�� IC�� val�es 
were determined by MTT assay �Fig. ��� ���. For VCR�� IC�� 
val�es for parental and VCR­resistant HL�� cells were 
4 nM and ��� nM respectively �see Fig. ����� whilst for 
Ara­C — ����� nM and � nM respectively �see Fig. ���. The 
res�lts indicated that the cells�� selected by VCR resistance�� 
also were resistant to Ara­C. HL­��/VCR cells�� which 
were more then 7�­fold resistant to VCR�� also showed 
4�­fold increased resistance to Ara­C. These data are in 
agreement with the res�lts of other a�thors [�����]. For 
example�� KF­�9 cell line resistant to adriamycin and VCR�� 
showed cross­resistance to Ara­C [�4]. In another st�dy 
it was shown that P��� cell line resistant to VCR also pos­
sessed cross­resistance to Ara­C [��].
Therape�tic strategies aiming to overcome 
MDR1 gene overexpression may be �sef�l in enhance­
ment cytotoxic effects of VCR. In this setting�� resistance 
to VCR can be reversed�� at least in vitro�� by variety of 
resistance modifying agents called MDR reversal mod�­
lators or chemosensitizers [��]. MDR mod�lators often 
reverse m�ltidr�g resistance by competing for the trans­
port system responsible for MDR. Apart from reversal 
mod�lators�� the antisense oligomers targeted MDR� 
mRNA may also res�lt in decrease and even loss of re­
sistance�� as there will be no P­gp synthesis.
In concl�sion�� we have shown that HL­�� cells�� 
adapted to higher concentrations of VCR�� express 
MDR1 gene at higher levels�� and also aq�ire cross­
resistance to Ara­C.
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Fig. 2. Effect of VCR on viability of HL�� �triangles�� and HL��/
VCR �circles�� cells. IC�� concentration of VCR was determined 
by MTT assay for each cell line in at least � independent experi­
ments�� in triplicate per point 
Fig. 3. Effect of Ara­C on viability of HL�� �triangles�� and 
HL��/VCR �circles�� cells. The IC�� concentration of Ara­C IC�� 
concentration was determined by MTT assay for each cell line in 
at least � independent experiments�� in triplicate per point
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ПЕРЕКРЕСТНАЯ УСТОЙЧИВОСТЬ К ЦИТОЗИНАРАБИНОЗИДУ 
КЛЕТОК ЛИНИИ HL60, УСТОЙЧИВЫХ К ВИНКРИСТИНУ
Целью работы было исследование участия Р-гликопротеина (Р-gp), продукта гена-1 множественной лекарственной устойчивости 
(MDR1) в устойчивости клеток лейкемии человека к винкристину (��Р) и перекрестной ре�истентности к �ито�инарабино�иду              
(Аrа-C). Методы: клетки острой миелоидной лейкемии линии HL60 кул�тивировали в среде с 1–50 нM ��Р в течение 4–6 нед,            
после чего были отселектированы ��Р-ре�истентные клетки (HL60/��Р). �лияние препаратов на жи�неспособност� клеток      
и�учали при помощи МТТ-метода, экспресию гена MDR1 — методом полимера�ной �епной реак�ии обратной транскрип�ии. 
Результаты: в клетках линии HL60экспрессиягена   MDR1 не была выявлена, но была �арегистрирована после инкуба�ии клеток 
с 2 нM ��Р, причем ее уровен� во�растал по мере повы�ения кон�ентра�ии ��Р в среде инкуба�ии. �ока�ано, что устойчи-                
вост� клеток линии HL-60/��Р к ��Р и Аrа-C в 75 и в 42 ра�а вы�е, соотвественно, чем таковая клеток линии HL60.                  Выводы: 
приобретенная устойчивост� к ��Р и перекрестная устойчивост� к Аrа-C коррелирует с уровнем экспрессии гена MDR1.
Ключевые слова: множественная устойчивост� к препаратам, P-гликопротеин, HL60, винкристин, �ито�инарабино�ид.   
